SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23:437455.MEDLINE
  • 2
    Beasley RP, Hwang LW, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 1981; 2:11291133.MEDLINE
  • 3
    Hoofnagle JH, Di Bisceglie AM. Treatment of chronic viral hepatitis. N Engl J Med 1997; 336:347356.MEDLINE
  • 4
    Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detxky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119:312323.MEDLINE
  • 5
    Niederau C, Heintges T, Lange S, Goldemann G, Niederau CM, Mohr L, Häussinger D. Long-term follow-up of HBeAg positive patients with chronic active hepatitis after α-interferon therapy. N Engl J Med 1996; 334:14221427.MEDLINE
  • 6
    Lau DT-Y, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113:16601667.MEDLINE
  • 7
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:16571661.MEDLINE
  • 8
    Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997; 113:12581263.MEDLINE
  • 9
    Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:6168.MEDLINE
  • 10
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann H-W L, Goodman Z, Crowther L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:12561263.MEDLINE
  • 11
    Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29:889896.MEDLINE
  • 12
    Hookoop P, de Man RA, Heitjtink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet 1995; 346:11561157.MEDLINE
  • 13
    Liaw Y-F, Chien R-N, Yeh C-T, Tsai S-L, Chu C-M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567572.MEDLINE
  • 14
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dushieko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711713.MEDLINE
  • 15
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in the HBV RNA dependent DNA polymerase confers resistance of lamivudine in vivo. Hepatology 1996; 24:714717.MEDLINE
  • 16
    Batholomew MM, Jansen RW, Jeffers LJ, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:2022.MEDLINE
  • 17
    De Man RA, Bartholomew AI, Niesters HGM, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998; 29:669675.MEDLINE
  • 18
    Urdea M. Synthesis and characterization of branched DNA (bDNA) for the direct and quantitative detection of CMV, HBV, HCV and HIV. Clin Chem 1993; 39:725726.
  • 19
    Lipka JJ, Chiba T, Kitamura M, Vickstrom R, Wiesner D, Yamada K, Kristman K, et al. Performance of automated chemiluminescent paramagnetic microparticle immunoassays for HBsAg, HBsAb, and HBcAb on the Abbott i2000 system [Abstract]. Clin Chem 1997; 43:S239.
  • 20
    Allen MI, Gauthier J, Des Lauriers M, Bourne EJ, Carrick KM, Baldanti F, Ross LL, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999; 37:33383347.MEDLINE
  • 21
    Stuyver L, Rossau R, Maertens G. Line probe assay for the detection of hepatitis B and C virus genotypes. Antiviral Ther 1996; 1:5357.
  • 22
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 95:15131520.
  • 23
    Liaw YF, Lai CL, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. Two-year lamivudine therapy in chronic hepatitis B infection: results of a placebo controlled multicentre study in Asia [Abstract]. Gastroenterology 1998; 114:A1289.
  • 24
    Chang T-T, Lai CL, Liaw Y-F, Leung NW, Ruan R, Lim SG, Lee CM, et al. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine [Abstract]. Hepatology 1999; 30:420A.
  • 25
    Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29:15811586.MEDLINE
  • 26
    Dienstag JL, Schiff ER, Mitchell M, Casey DE, Gitlin N, Lissoos T, Gelb LD, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30:10821087.MEDLINE
  • 27
    Atkins M, Hunt CM, Brown N, Gray F, Sanathanan L, Woessner M, Lai CL, et al. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients [Abstract]. Hepatology 1998; 28:319A.
  • 28
    Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistance to 3′thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90:56535656.MEDLINE
  • 29
    Hoofnagle JH, Hanson RG, Minuk GY, Pappas SC, Schafer DF, Dusheiko GM, Straus SE, et al. Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 1984; 86:150157.MEDLINE
  • 30
    McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333:10991105.MEDLINE
  • 31
    Schiff E, Cianciara J, Kowdley K, Norkrans G, Perrillo R, Tong M, Crowther L, et al. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials [Abstract]. Hepatology 1998; 28:163A.
  • 32
    Dimou E, Papatheodoridis GV, Laras A, Hadziyannis SJ. Efficacy of long-term lamivudine monotherapy in HBeAg negative chronic hepatitis B [Abstract]. Antiviral Ther 2000; 5(Suppl 1):44.
  • 33
    Chen R-N, Liaw Y-F, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30:770774.MEDLINE
  • 34
    Gilson RJC, Chopra K, Murray-Lyon I, Newell A, Nelson M, Tedder RS, Toole J, et al. A placebo-controlled phase I/II study of adefovir dipivoxil (BIS-POM PMEA) in patients with chronic hepatitis B infection [Abstract]. Hepatology 1996; 24:281A.
  • 35
    Ono-Nita SK, Kato N, Shiratori Y, Lan K-H, Yoshida H, Carrilho FJ, Omata M. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103:16351640.MEDLINE
  • 36
    Peters M, Angus P, Dickson R, Min A, Perrillo R, Schiff E, Wright T, et al. Adefovir dipivoxil treatment of hepatitis B virus disease in patients failing lamivudine therapy [Abstract]. Antiviral Ther 2000; 5(Suppl 1):45.
  • 37
    Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998; 42:32003208.MEDLINE
  • 38
    Chu CK, Ma T, Shanmuganathan K, Wang C, Xiang Y, Pai SB, Yao G-Q, et al. Use of 2′-fluoro-5-methyl-B-L-arabinofuranosyl-uracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995; 39:979981.MEDLINE
  • 39
    Bryant ML, Gosselin G, Imbach J-L, Schinzai RF, Sommadossi J-P. Antiviral B-L-2′-deosynucleosides specific for hepatitis B virus infection [Abstract]. Antiviral Ther 2000; 5(Suppl 1):B56.